New Parkinson's drug candidate passes early safety check
NCT ID NCT04291859
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early study tested a new drug called Lu AF28996 in 57 people with Parkinson's disease. The main goal was to see if the drug is safe and how the body handles it. Researchers measured side effects and drug levels in the blood. This is a first step to see if the drug might help control symptoms in the future.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Lu AF28996
What this could lead to
If successful, this could point toward a new medication to help control Parkinson's symptoms.
What could go wrong
This is a very early Phase 1 study focused on safety, not effectiveness. The drug may not work or could have side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PARKINSON DISEASE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Atlanta Center for Medical Research
Atlanta, Georgia, 30331, United States
-
Caen Normandy University
Caen, Basse-Normandie, 14033, France
-
CenExel Los Alamitos
Los Alamitos, California, 90720, United States
-
Curiositas-ad-sanum
Hamburg, 83527, Germany
-
Georgetown University
Washington D.C., District of Columbia, 20007, United States
-
Hawaii Pacific Neuroscience
Honolulu, Hawaii, 96817, United States
-
Hosp. General Catalunya
Mira-Sol, 08195, Spain
-
Hospital Vall d´Hebron
Barcelona, 08035, Spain
-
Inland Nortwest Research
Spokane, Washington, 99202, United States
-
Neurology Consultants of Nebraska
Omaha, Nebraska, 68154, United States
-
Parkinson's Disease Treatment Center of SW FL
Port Charlotte, Florida, 33980, United States
-
QPS Netherlands BV
Leeuwarden, 8934 AD, Netherlands
-
QUEST Research Institute
Farmington Hills, Michigan, 48334, United States
-
Velocity
Hallandale, Florida, 33009, United States
-
Virgen Del Roccio
Seville, 41013, Spain